160 related articles for article (PubMed ID: 36219903)
1. Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitors.
Zhang J; Dong Y; Gao S; Zhang X; Liao H; Shi X; Zhang Z; Zhao T; Liang R; Qi D; Wu T; Pang J; Liu X; Zhan P
Eur J Med Chem; 2022 Dec; 244():114816. PubMed ID: 36219903
[TBL] [Abstract][Full Text] [Related]
2. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
Miner JN; Tan PK; Hyndman D; Liu S; Iverson C; Nanavati P; Hagerty DT; Manhard K; Shen Z; Girardet JL; Yeh LT; Terkeltaub R; Quart B
Arthritis Res Ther; 2016 Oct; 18(1):214. PubMed ID: 27716403
[TBL] [Abstract][Full Text] [Related]
3. Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.
Zhao T; Meng Q; Sun Z; Chen Y; Ai W; Zhao Z; Kang D; Dong Y; Liang R; Wu T; Pang J; Liu X; Zhan P
J Med Chem; 2020 Oct; 63(19):10829-10854. PubMed ID: 32897699
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Flexible Naphthyltriazolylmethane-based Thioacetic Acids as Highly Active Uric Acid Transporter 1 (URAT1) Inhibitors for the Treatment of Hyperuricemia of Gout.
Zhang X; Wu J; Liu W; Liu Y; Xie Y; Shang Q; Zhou Z; Xu W; Tang L; Wang J; Zhao G
Med Chem; 2017; 13(3):260-281. PubMed ID: 27633583
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.
Zhao T; Zhang J; Tao Y; Liao H; Zhao F; Liang R; Shi X; Zhang Z; Ji J; Wu T; Pang J; Liu X; Zhan P
J Med Chem; 2022 Mar; 65(5):4218-4237. PubMed ID: 35084182
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a Novel Thienopyrimidine Compound as a Urate Transporter 1 and Glucose Transporter 9 Dual Inhibitor with Improved Efficacy and Favorable Druggability.
Shi X; Zhao T; Wang S; Xu S; Liao H; Gao S; Gao Z; Zhang J; Qi D; Zhang Z; Zheng F; Wang Y; Wang Z; Yang M; Yang Q; Yi F; Pang J; Liu X; Zhan P
J Med Chem; 2024 Mar; 67(6):5032-5052. PubMed ID: 38482820
[TBL] [Abstract][Full Text] [Related]
7. Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019).
Dong Y; Zhao T; Ai W; Zalloum WA; Kang D; Wu T; Liu X; Zhan P
Expert Opin Ther Pat; 2019 Nov; 29(11):871-879. PubMed ID: 31593642
[No Abstract] [Full Text] [Related]
8. Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia.
Zhao Z; Liu J; Kuang P; Luo J; Surineni G; Cen X; Wu T; Cao Y; Zhou P; Pang J; Zhang Q; Chen J
Eur J Med Chem; 2022 Feb; 229():114092. PubMed ID: 34998055
[TBL] [Abstract][Full Text] [Related]
9. CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia.
Zhao ZA; Jiang Y; Chen YY; Wu T; Lan QS; Li YM; Li L; Yang Y; Lin CT; Cao Y; Zhou PZ; Guo JY; Tian YX; Pang JX
Acta Pharmacol Sin; 2022 Jan; 43(1):121-132. PubMed ID: 33767379
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a Flexible Triazolylbutanoic Acid as a Highly Potent Uric Acid Transporter 1 (URAT1) Inhibitor.
Tian H; Liu W; Zhou Z; Shang Q; Liu Y; Xie Y; Liu C; Xu W; Tang L; Wang J; Zhao G
Molecules; 2016 Nov; 21(11):. PubMed ID: 27854343
[TBL] [Abstract][Full Text] [Related]
11. Proline-derived quinoline formamide compounds as human urate transporter 1 inhibitors with potent uric acid-lowering activities.
Li S; Liao H; Luo L; Meng B; Zheng F; Sheng L; Zhao H; Huan Y; Lei L; Zhai J; Zhao K; Tian J; Wu T; Li G; Pang J; Huang H
Eur J Med Chem; 2024 Apr; 269():116327. PubMed ID: 38547733
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of 3-phenyl substituted pyridine derivatives as potential dual inhibitors of XOR and URAT1.
Yang C; Cai H; Zhu X; Zhang L; Li J
Eur J Med Chem; 2024 May; 271():116407. PubMed ID: 38663283
[TBL] [Abstract][Full Text] [Related]
13. Systematic Structure-Activity Relationship (SAR) Exploration of Diarylmethane Backbone and Discovery of A Highly Potent Novel Uric Acid Transporter 1 (URAT1) Inhibitor.
Cai W; Wu J; Liu W; Xie Y; Liu Y; Zhang S; Xu W; Tang L; Wang J; Zhao G
Molecules; 2018 Jan; 23(2):. PubMed ID: 29382075
[TBL] [Abstract][Full Text] [Related]
14. Lesinurad: A Review in Hyperuricaemia of Gout.
Deeks ED
Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation and 3D-QSAR studies of 1,2,4-triazole-5-substituted carboxylic acid bioisosteres as uric acid transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia associated with gout.
Wu JW; Yin L; Liu YQ; Zhang H; Xie YF; Wang RL; Zhao GL
Bioorg Med Chem Lett; 2019 Feb; 29(3):383-388. PubMed ID: 30579795
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents.
Zhao Z; Liu J; Yuan L; Yang Z; Kuang P; Liao H; Luo J; Feng H; Zheng F; Chen Y; Wu T; Guo J; Cao Y; Yang Y; Lin C; Zhang Q; Chen J; Pang J
Eur J Med Chem; 2022 Nov; 242():114682. PubMed ID: 36001935
[TBL] [Abstract][Full Text] [Related]
17. Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase.
Chen Y; Zhao Z; Li Y; Yang Y; Li L; Jiang Y; Lin C; Cao Y; Zhou P; Tian Y; Wu T; Pang J
Phytomedicine; 2021 Jan; 80():153374. PubMed ID: 33075645
[TBL] [Abstract][Full Text] [Related]
18. Discovery of digallic acid as XOD/URAT1 dual target inhibitor for the treatment of hyperuricemia.
Zheng F; Mai S; Cen X; Zhao P; Ye W; Ke J; Lin S; Hu H; Guo Z; Zhang S; Liao H; Wu T; Tian Y; Zhang Q; Pang J; Zhao Z
Bioorg Chem; 2024 Jun; 147():107381. PubMed ID: 38669781
[TBL] [Abstract][Full Text] [Related]
19. Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020-present).
Shi X; Zhao T; da Silva-Júnior EF; Zhang J; Xu S; Gao S; Liu X; Zhan P
Expert Opin Ther Pat; 2022 Dec; 32(12):1175-1184. PubMed ID: 36625031
[TBL] [Abstract][Full Text] [Related]
20. Paeonia × suffruticosa Andrews leaf extract and its main component apigenin 7-O-glucoside ameliorate hyperuricemia by inhibiting xanthine oxidase activity and regulating renal urate transporters.
Zhang Y; Li Y; Li C; Zhao Y; Xu L; Ma S; Lin F; Xie Y; An J; Wang S
Phytomedicine; 2023 Sep; 118():154957. PubMed ID: 37478683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
